Please login to the form below

Not currently logged in
Email:
Password:

GLP-1

This page shows the latest GLP-1 news and features for those working in and with pharma, biotech and healthcare.

Sanofi exits Zynquista alliance with Lexicon

Sanofi exits Zynquista alliance with Lexicon

The Sanofi/Lexicon partnered drug for type 1 diabetes was being co-developed as an add-on therapy to insulin injections to help improve blood sugar control. ... as stimulating the release of GLP-1.

Latest news

  • Novo Nordisk shareholder revolt reaches Europe Novo Nordisk shareholder revolt reaches Europe

    Novo Nordisk has latterly become less reliant on sales of its insulin products as newer products, particularly GLP-1 agonists Victoza (liraglutide) and Ozempic (semaglutide), have increased their share of revenues.

  • Novo Nordisk boosted by new type 2 diabetes launches Novo Nordisk boosted by new type 2 diabetes launches

    Rapid uptake of newcomer Ozempic aids growth. Novo Nordisk’s expansion into a series of glucagon-like peptide 1 (GLP-1) products has helped boost sales despite loosing ground in the ... GLP-1 drugs are a relatively new group of treatments for type 2

  • Boehringer taps Korea’s Bridge for Ofev follow-up Boehringer taps Korea’s Bridge for Ofev follow-up

    Bridge stands to receive up to 1.1bn ($1.24bn) under the terms of the deal, including 45m in upfront and near-term payments. ... Meanwhile, the $870m agreement with Yuhan focuses on the development of dual agonists of fibroblast growth factor 21 (FGF21)

  • Boehringer bolsters NASH pipeline with $870m Yuhan deal Boehringer bolsters NASH pipeline with $870m Yuhan deal

    The partners want to develop a first-in-class dual agonist that will target both FGF21 and glucagon-like peptide-1 (GLP-1), a well-characterised target for diabetes and obesity ... therapies. Boehringer is a diabetes specialist and already has a dual

  • Lilly’s Trulicity cuts heart and kidney risks in diabetes by 12% Lilly’s Trulicity cuts heart and kidney risks in diabetes by 12%

    Lilly revealed last November that the top-line data with the once-weekly GLP-1 agonist was positive, and over the weekend at the American Diabetes Association meeting, presented the detailed ... The big question is whether the size of the improvements is

More from news
Approximately 13 fully matching, plus 144 partially matching documents found.

Latest Intelligence

  • Harnessing commercial innovation Harnessing commercial innovation

    These efforts moved up a gear last year when Novo decided to enter into phase III trials with an oral GLP-1.

  • Oral biologics delivery still elusive Oral biologics delivery still elusive

    like peptide-1 (GLP-1), a hormone that works independently of insulin to stimulate glucose release. ... Oramed - whose technology relies on encapsulating the peptide or protein and delivering it alongside enzyme inhibitors and permeation enhancers - has

  • Deal Watch November 2015 Deal Watch November 2015

    Included in the package are three products: a weekly insulin, a fixed weekly dose combination of GLP-1-RA/insulin and efpeglenatide, a long acting glucagon like peptide-1 receptor agonist. ... 6, 546. Hanmi Pharmaceutical. Sanofi. Licence. Three diabetes

  • Medius Deal Watch table for April 2015 Medius Deal Watch table for April 2015

    400. Inarcia therapeutics / Investors. Synthetic royalty rights. ICTA650 extended sub-cutaneous delivery of GLP-1 for T2DM.

  • Deal Watch table for January 2015 Deal Watch table for January 2015

    Licence collaboration agreement. 1, 110. Janssen/ Depomed. Nucynta [tapentadol] franchise including extended release tablets and oral solutions. ... Asset acquisition. 142.  Amunix/Naia. To develop glucagon peptide agonists GLP-1-XTEN and GLP-2-XTEN in

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

Alzheimers
Detecting Alzheimer’s ahead of a cure
A focus on promising new research...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...
Can you survive without the blue dot?
Or has the digital world has replaced our brain...

Infographics